The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
The Seattle-based company is one of several that have raised venture capital and equity investment funding this week.
Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.